PaulAGoepfertMD
Infectious Disease • Birmingham, ALProfessor, Medicine, University of Alabama School of Medicine
Dr. Goepfert is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
619 19th St S
Birmingham, AL 35233Phone+1 205-934-6600
Education & Training
University of Alabama Medical CenterFellowship, Infectious Disease, 1994 - 1997- University of Alabama Medical CenterResidency, Internal Medicine, 1991 - 1994
Baylor College of MedicineClass of 1991
Certifications & Licensure
AL State Medical License 1992 - 2025
TX State Medical License 1992 - 1997
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2010
Clinical Trials
- Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
- Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth Start of enrollment: 2002 Dec 01
- Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults Start of enrollment: 2006 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.Holly Janes, Leigh H Fisher, Jia Jin Kee, Lalitha Parameswaran, Paul A Goepfert
The Journal of Infectious Diseases. 2024-12-16 - Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial.Lindsay N Carpp, Ollivier Hyrien, Youyi Fong, David Benkeser, Sanne Roels
Nature Communications. 2024-11-12 - Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.Youyi Fong, Lauren Dang, Bo Zhang, Jonathan Fintzi, Shiyu Chen
Clinical Infectious Diseases. 2024-09-26
Press Mentions
Memory B Cell Marker Predicts Long-Lived Antibody Response to Flu VaccineMarch 22nd, 2023- Indians Remain Wary of Booster Doses as Covid Wanes and Side-Effect Worries RiseJanuary 17th, 2023
- UAB Vaccine Research Clinic Talks New Booster ShotAugust 31st, 2022
- Join now to see all
Grant Support
- CTL And HIV Polymorphisms In Heterosexual TransmissionNational Institute Of Allergy And Infectious Diseases2010–2012
- HIV-1 Cryptic Epitopes: Implications For Vaccine DesignNational Institute Of Allergy And Infectious Diseases2009–2011
- ClinicalNational Institute Of Allergy And Infectious Diseases2008–2011
- HIV-1 Suppression By MHC Class I Restricted CD8 T CellsNational Institute Of Allergy And Infectious Diseases2007–2008
- Alabama/Zambia HIV Vaccine Clinical Trials Unit (HVTU)National Institute Of Allergy And Infectious Diseases2004–2006
- CD8+ T Cell Cytokine Production In HIV-1 InfectionNational Institute Of Allergy And Infectious Diseases2002–2005
- CD8+ T Cell Cytokine Production In HIV-1 InfectionNational Institute Of Allergy And Infectious Diseases2001
- Human Foamy Virus Structural ProteinsNational Institute Of Allergy And Infectious Diseases1996–2000
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
